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6/j.bSystemic exposure to high-dose busulfan has been correlated with efficacy and toxicity after hematopoietic
cell transplantation for malignancy.We used the area under the concentration-time curve (AUC) to prospec-
tively determine the maximally tolerated systemic exposure to i.v. busulfan when given once daily after
fludarabine administered at 40 mg/m2 for 4 days. Three target AUC levels were planned: 6,000, 7,500, and
9,000 mM-min. Included were patients 16 to 65 years old, with a hematologic malignancy, an HLA A, B, or
C, DRB1 8/8 or 7/8 matched donor, Karnofsky performance status $70%, and adequate organ function.
For level 1 patients, i.v. busulfan doses 1 and 2 were 170 mg/m2/day, then doses 3 and 4 were adjusted based
on first-dose pharmacokinetic modeling to achieve an average daily AUC of 6,000 mM-min. Doses 1 and 2 for
the subsequent cohorts were based on the level 1 data: 180 mg/m2/day for AUC 7,500 mM-min (level 2) and
220 mg/m2/day for AUC 9,000 mM-min (level 3), with pharmacokinetic targeting for doses 3 and 4. Pharma-
cokinetic analysis after the last dose showed that 88% of the patients had been exposed to ameanAUCwithin
10%of the target. Forty patientswere treated at level 1, 29 patients at level 2, and three patients at level 3. DLT
was veno-occlusive disease of the liver, which occurred in noneof 40 patients (0%) at level 1, twoof 29 patients
(7%) at level 2, and three of three patients (100%) at level 3. Dermatitis (P\ .01) and pulmonary toxicity
(P 5 .01) were also increased at higher AUC levels. Level 2 (7,500 mM-min  4 days) was the maximally
tolerated AUC. Within the confines of the trial’s small sample size, there was no suggestion that escalating
busulfanAUC from6,000 to 7,500 mM-min 4 days increased nonrelapsemortality. Assessment of the higher
busulfan AUC on relapse prevention requires trials in patients with a homogeneous risk of relapse.
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.00
bmt.2011.12.584200 mg/kg (BuCy), the maximally tolerated dose
of busulfan was 16 mg/kg, administered orally as
1 mg/kg every 6 hours for 4 days. Later studies eval-
uating the relationship between busulfan pharma-
cokinetic parameters and clinical outcomes showed
that systemic exposure to busulfan was an important
predictor of toxicity and efficacy so that many centers
began dose-adjusting busulfan to optimize systemic
exposure [2-6]. An i.v. formulation of busulfan
affords more reliable bioavailability based on
studies demonstrating that an i.v. dose of 0.8 mg/kg
was equivalent and produced less variable
pharmacokinetics than an oral dose of 1 mg/kg [7-9].
More recently, busulfan-based regimens, other than
BuCy, have been investigated in an effort to eliminate
the toxicity associated with cyclophosphamide. One
such regimen is fludarabine and busulfan (FluBu),
which has become a commonly used conditioning
regimen for allogeneicHCT. Initially, busulfan dosing
in the FluBu regimen was based on the dose used in1099
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possible, and this schedule has been shown to be safe
and more convenient [11-13]. Retrospective analyses
demonstrate that relationships also exist between
busulfan systemic exposures and clinical outcomes
with the FluBu regimen [13,14], but no prospective
studies have evaluated the maximally tolerated dose
(MTD) of busulfan in this setting. In patients with
advanced malignant diseases, posttransplantation
relapse continues to be a frequent cause of mortality.
When used in combination with fludarabine, the dose
(or systemic exposure) of busulfan could perhaps be
escalated to a new MTD, which may result in fewer
posttransplantation relapses without increasing
regimen-related toxicity and mortality. Based on this
premise, we designed a prospective busulfan dose-
escalation study. Building on the data showing correla-
tion between clinical outcomes and busulfan systemic
exposure, we based the dosing schema on area under
the concentration time curve (AUC) targets, rather
than specific doses. By escalating AUCs with the use
of individual pharmacokinetic profiling with dose ad-
justment, we also reduced the effect of interpatient var-
iability in clearance. Our primary objective was to
define the maximally tolerated busulfan AUC and
dose-limiting toxicities when administered as part of
the FluBu conditioning before allogeneic stem cell
transplantation. Our secondary objectives were to cor-
relate busulfan AUC dose levels to toxicity, nonrelapse
mortality, relapse, and survival.PATIENTS AND METHODS
Patients
This study was reviewed and approved by the
University of South Florida Institutional Review
Board and registered with clinicaltrials.gov
(NCT00361140). All patients provided written in-
formed consent. Enrollment in the study began
September 16, 2005, and ended July 2, 2010. Follow-
up of patients was through April 30, 2011. Patients
were eligible if they had a diagnosis of hematologic
malignancy or myeloproliferative disorder, were
between the ages of 16 and 65, had a related or unre-
lated donor compatible for 10/10 or 9/10 HLA A, B,
or C, DRB1, and DQB1 alleles (the protocol was later
amended to allow donors compatible for 8/8 or 7/8
HLA A, B, or C, and DRB1 loci, given the reported
lack of correlation between DQ mismatches and
adverse outcomes) [15], Karnofsky performance status
70% to 100%, diffusing capacity of the lung for carbon
monoxide (DLCO) greater than 50% of predicted
values, left ventricular ejection fraction greater than
45%, creatinine clearance greater than or equal to
50 mL/min, total bilirubin less than or equal to
2 mg/dL, and serum transaminases less than two timesthe institutional upper limit of normal. Excluded were
patients with active infection, central nervous system
(CNS) malignancy, human immunodeficiency virus
or hepatitis seropositivity, history of chronic
hepatitis, pregnancy or lactation, current use of metro-
nidazole or acetaminophen, prior treatment with gem-
tuzumab ozogamicin, prior HCT (either allogeneic or
autologous), prior chest or abdominal irradiation with
greater than 1,800 cGy, history of myocardial infarc-
tion or coronary artery disease less than 6 months be-
fore enrollment, congestive heart failure, peripheral
vascular disease, untreated thoracic or abdominal an-
eurysm, history of cerebrovascular accident, dementia,
connective tissue/rheumatologic disorders, uncon-
trolled diabetes, history of prior malignancy (exclud-
ing nonmelanoma skin or cervical carcinoma after
curative resection) less than 5 years from enrollment,
or history of renal failure requiring renal replacement
therapy. Disease status was categorized as early, inter-
mediate, or advanced per the Center for International
Blood and Marrow Transplant Research [16]. HCT
comorbidity index (HCT-CI) was assessed retrospec-
tively according to Sorror et al. [17].
Donors
All donors had high-resolutionmolecular typing for
HLA-DRB1 and HLA-DQB1. Unrelated donors had
sequence-based typing for HLA-A, B, and C, whereas
related donors had low-intermediate resolutionmolecu-
lar typing of HLA-A, B, and C. All patients were to
receive unmanipulated granulocyte-colony stimulating
factor mobilized peripheral blood hematopoietic cells.
Conditioning Regimen
Fludarabine (Fludara; Genzyme Inc., Cambridge,
MA) 40 mg/m2 was given intravenously over 1 hour on
days 6, 5, 4, and 3. All patients had creatinine clearances
above 70 mL/min, so no dosing adjustments were re-
quired per the manufacturer’s recommendations. Each
dose of fludarabine was immediately followed by intra-
venous busulfan (Busulfex;OtsukaAmericaPharmaceu-
tical, Inc., Rockville, MD) over 3 hours on days 6, 5, 4,
and 3 infused via a controlled rate infusion pump.
Body surface area was determined using actual body
weight.TargetedAUClevelswere as follows:AUClevel
1: 6,0006 600 mM-min; AUC level 2: 7,5006 750 mM-
min; andAUC level 3: 9,0006 900mM-min.We started
with a target AUC of 6,000 mM-min based on previous
studies that demonstrated no correlation between aver-
age AUC values of 4,000 to 6,000 mM-min with
treatment-related mortality [9,10,12,13]. The day 6
and 5 doses of busulfan for patients on level 1 was 170
mg/m2. Subsequent daily doses for patients on level 1
were adjusted to achieve an average daily AUC of
6,000 mM-min over the 4-day administration period.
The level 1 dose of 170 mg/m2 was chosen based on
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and our own institutional data when using a dose of 130
mg/m2. The starting busulfan dose for level 2 was
180mg/m2and for level 3was 220mg/m2, basedon level
1 pharmacokinetic data and previously shown busulfan
linear pharmacokinetics. Allogeneic peripheral blood
hematopoietic cells were infused on day 0, at least 36
hours after the last dose of busulfan. Patients with
mismatched unrelated donor grafts were given rabbit
antithymocyte globulin (rATG; Thymoglobulin; Gen-
zyme Corporation, Cambridge, MA) 1 mg/kg
intravenously on day 3 followed by 3.25 mg/kg/day on
day 2 and day 1.
Dose Escalation
Twenty patients were to be accrued per level to in-
crease the confidence of a cause-and-effect relationship
between the observed toxicity and busulfan exposure.
Stopping parameters were dose-limiting toxicity
(information to follow) seen in three of four patients,
four of five patients, five of seven patients, six of 12 pa-
tients, seven of 14 patients, eight of 16 patients, nine of
18 patients, or 10 of 20patients. If this occurred atAUC
level 1, the study would be terminated. If this occurred
atAUC level 2 or 3, the prior levelwouldbe determined
to be themaximally toleratedAUC, and a total of 30 pa-
tients would be accrued to that AUC level.
Busulfan Pharmacokinetic Analysis
Blood samples were drawn after the first dose of
busulfan at 15 minutes after the end of the busulfan in-
fusion then at 5, 7, 9, and 12 hours after the start of the
infusion. The above sampling was repeated around the
fourth dose with the addition of a pre-dose sample.
Samples were drawn from the patient’s central venous
catheter from a lumen other than the lumen being used
for busulfan infusion. Before withdrawing the sample,
standard flushing procedures were performed, and 10
mL of blood was withdrawn and discarded. Plasma
was prepared, frozen, and shipped overnight to the
Hospital of the University of Pennsylvania Clinical
Toxicology Laboratory where pharmacokinetic analy-
ses were performed. Samples were analyzed using gas
chromatography/mass spectroscopy with selected ion
monitoring [18]. The busulfan steady-state AUC was
estimated from concentration data using the single-
compartment first-order elimination model for i.v. in-
fusion using WinNonlin, v4.1, in compliance with the
company’s ‘‘acceptable use policy’’ (Pharsight Corp.,
Mountain View, CA).
Supportive Care
Patients received antiseizure prophylaxis with lora-
zepam 0.5 mg orally or i.v. every 6 hours starting 24
hours before and continuing until 24 hours after busul-
fan administration. Ursodiol was given to prevent hep-atotoxicity. Patients were not to receive concurrent
metronidazole, itraconazole, or acetaminophen during
the chemotherapy period; other azoles were permitted.
Graft-versus-host disease (GVHD) prophylaxis con-
sisted of tacrolimus and methotrexate, tacrolimus and
mycophenolate mofetil, or tacrolimus and sirolimus,
depending on concurrent clinical trials ongoing at
our institution. Patients did not routinely receive
granulocyte-colony stimulating factor posttransplan-
tation. Standard antimicrobial prophylaxis and viral
surveillance per institutional guidelines were used to
prevent infections.
Toxicity and Engraftment
Regimen-related toxicity through day 100 was
evaluated by the Common Terminology Criteria for
Adverse Events version 3 (http://www.ctep.cancer.
gov/reporting/ctcnew.html). Hepatic veno-occlusive
disease/sinusoidal obstructive syndrome (VOD/SOS)
was diagnosed and staged according to criteria set
forth by McDonald et al [19] as well as findings on ul-
trasound with Doppler evaluation, biopsy, and hemo-
dynamic evaluation when possible. Dose-limiting
toxicity (DLT) was defined as any one of the following:
mortality within 100 days posttransplantation without
evidence of persistent or recurrent malignancy, any
seizure occurring within 72 hours of busulfan adminis-
tration, severe VOD/SOS, or grade 4 toxicity (unless
related to GVHD or infection) occurring within the
first 100 days posttransplantation in the following
categories: cardiac, gastrointestinal, hepatobiliary, hy-
perbilirubinemia on at least two consecutive measure-
ments at least 24 hours apart, pulmonary, or renal.
Patients were not evaluable for specific regimen-
related toxicities if they developed concomitant toxic-
ities related to infection or GVHD.
Neutrophil engraftment was defined as the first day
that the absolute neutrophil count is greater than 0.5
109/L on three consecutive days. Platelet engraftment
was defined as the first day greater than 20  109/L
on three consecutive days without transfusion for at
least 7 days.Day 0was considered the day of platelet en-
graftment for patients in whom the platelet count did
not nadir\20  109/L. Chimerism studies were done
at or about posttransplantation day 30, 90, 180, and
365using a polymerase chain reaction/short tandemre-
peat method on unsorted bone marrow samples. In ad-
dition, patients had peripheral blood CD3/CD33
subsets isolated by fluorescence-activated cell sorting
and subsequently analyzed for donor chimerism [20].
Acute GVHDwas graded up to day 100 posttransplan-
tation using consensus criteria [21]. Chronic GVHD
was graded after day 100 as mild, moderate, or severe
based on the National Institutes of Health Consensus
Development Project [22]. Patients were censored for
the assessment of GVHD at the time of relapse or non-
relapse mortality from causes other than GVHD.
Table 1. Patient Characteristics
AUC Level
P
value
1
6,000
(n 5 40)
2
7,500
(n 5 29)
3
9,000
(n 5 3)
Age (years) 49 44 54 .18
Median (range) (22-65) (23-62) (46-59)
Gender (M:F) 24:16 12:17 0:3 .06
Diagnosis .33
AML 15 (37.5%) 10 (34%) 2 (67%)
MDS/CMML 8 (20%) 5 (17%) 0
Myelofibrosis 5 (12.5%) 1 (4%) 1 (33%)
ALL 6 (15%) 10 (34%) 0
CML 1 (2.5%) 2 (7%) 0
NHL 5 (12.5%) 1 (4%) 0
CIBMTR disease risk .09
Early 21 (52.5%) 19 (66%) 1 (33%)
Intermediate 1 (2.5%) 3 (10%) 1 (33%)
Advanced 18 (45%) 7 (24%) 1 (33%)
HCT-CI .62
0 6 (15%) 6 (20%) 1 (33%)
1-2 17 (42.5%) 15 (52%) 1 (33%)
$3 17 (42.5%) 8 (28%) 1 (33%)
KPS .04
100% 20 (50%) 7 (24%) 0
90% 13 (32.5%) 18 (62%) 2 (67%)
#80% 7 (17.5%) 4 (14%) 1 (33%)
Donor .23
Matched related 26 (65%) 12 (41%) 1 (33%)
Matched unrelated 13 (32.5%) 15 (52%) 2 (67%)
Mismatched unrelated 1 (2.5%) 21 (7%) 0
GVHD prophylaxis .02
Tacrolimus/MTX 31 (77.5%) 22 (76%) 2 (67%)
Tacrolimus/MMF 9 (22.5%) 2 (7%) 1 (33%)
Tacrolimus/sirolimus 0 5 (17%) 0
Cytomegalovirus serology
(pretransplant); recipient:donor
.60
N:N 13 (32.5%) 7 (24%) 0
N:P 3 (7.5%) 4 (14%) 1 (33%)
P:P 15 (35%) 8 (28%) 1 (33%)
P:N 10 (25%) 10 (34%) 1 (33%)
AUC indicates area under the curve; M, male; F, female; AML, acute my-
elogenous leukemia; MDS/CMML, myelodysplastic syndrome/chronic
myelomonocytic leukemia; ALL, acute lymphoblastic leukemia; CML,
chronic myelogenous leukemia; NHL, non-Hodgkin lymphoma;
CIBMTR, Center for International Blood and Marrow Transplant Re-
search; HCT-CI, hematopoietic cell transplant comorbidity index; KPS,
Karnofsky performance status; GVHD, graft-versus-host disease;
MTX, methotrexate; MMF, mycophenolate mofetil; N:N, recipient
seronegative, donor seronegative; N:P, recipient seronegative, donor
seropositive; P:P, recipient seropositive, donor seropositive; P:N,
recipient seropositive, donor seronegative.
HLA DQ antigen mismatch (1 patient) and HLA B antigen and DQ allele
mismatch (1 patient); both patients received anti-thymocyte globulin
(ATG).
CIBMTR disease risk: early 5 first complete remission (CR), first
chronic phase (CP), MDS-refractory anemia or MDS-refractory anemia
with ringed sideroblasts; intermediate 5 second or subsequent CR or
CP or accelerated phase AP; advanced phase 5 primary induction fail-
ure, active disease, blastic phase, MDS-refractory anemia with excess
blasts or CMML.
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The dose escalation rules were based on a 0.15
probability of declaring the dose too toxic if the true
toxicity rate was 28% and a 0.76 probability of declar-
ing it too toxic if that rate was 50%. These operatingcharacteristics are based on a review of our database
of patients treated with BuCy that showed a 28% inci-
dence of the toxicities that were defined as dose limit-
ing. We were willing to accept this level of toxicity to
evaluate the potential therapeutic benefit of higher
doses of busulfan.
For descriptive purposes, categorical and continu-
ous variables are summarized as frequencies or per-
centages and as the median and range, respectively.
Differences in the median for continuous variables
were assessed by Wilcoxon rank-sum test. Differences
in frequencies were assessed by the Fisher exact test.
Overall survival and relapse-free survival were esti-
mated from the date of transplantation using the
Kaplan-Meier method. Survival curves among sub-
groups were compared using the log-rank test. Cumu-
lative incidences of neutrophil and platelet recovery,
acute and chronic GVHD, and relapse and nonrelapse
mortality were generated and compared using the
method of Gray [23]. The 95% confidence intervals
for point estimates of cumulative incidence, overall
survival, and relapse-free survival were driven based
on the log-log transformation [24].
RESULTS
Patients
Seventy-two patients received transplantations on
study (Table 1). Patient characteristics were similar
across levels with the exception of performance status
and GVHD prophylaxis. Level 1 seemed to have
a larger proportion of patients with a Karnofsky per-
formance status of 100%. Patients on level 1 were
co-enrolled on a GVHD prophylaxis study on which
patients were randomly assigned to either tacrolimus
and methotrexate (MTX) or tacrolimus and mycophe-
nolate mofetil (MMF) [25]. Analysis of the first 20 pa-
tients treated on level 1 showed satisfactory safety
endpoints and did not meet the predefined stopping
rules. However, when data were analyzed according
to the two types of GVHD prophylaxis administered,
there was a higher than desirable incidence of grades
III/IV GVHD (MTX 1/12; MMF 3/8; P 5 .15) and
1-year nonrelapse mortality (MTX 3/12; MMF 4/8;
P5 .27). Therefore, the investigators agreed to accrue
an additional 20 patients at AUC level 1 using a uni-
form GVHD prophylaxis regimen of tacrolimus and
MTX. After the complete results of the GVHD pro-
phylaxis study were analyzed and showed no difference
in grade 3 to 4 acute GVHD (aGVHD) or nonrelapse
mortality [25], GVHD prophylaxis was liberalized for
the rest of the trial, and the results for all 40 level 1
patients were pooled.
Busulfan Dosing and Pharmacokinetics
Fifty-one patients (71%) required dose adjust-
ments, and 63 (88%) achieved their target AUC
Table 2. Busulfan Dosing and Pharmacokinetic Parameters
AUC Level
P Value
1
6,000
(n 5 40)
2
7,500
(n 5 29)
3
9,000
(n 5 3)
Mean daily busulfan dose, mg/m2; median (range) 169 (90-223) 180 (147-246) 232 (148-266) <.001
Mean AUC, dose 1 and dose 4 (micromole*min/L);
median (range)
6,002 (4,846-7,018) 7,573 (5,920-9,502) 8,899 (8,784-8,955) <.001
Dose 1 AUC (micromole*min/L); median (range, CV) 6,538 (4,597-11,313; 23%) 7,579 (5,509-9,215; 14.7%) 8,523 (7,472-13,314; 31.9%) .03
Dose 4 AUC (micromole*min/L); median (range, CV) 5,454 (1,258-8,952; 34%) 7,662 (5,024-11,855; 22.8%) 9,387 (4,254-10,325; 40.9%) <.001
Dose 1 Cl (mL/min/m2); median (range, CV) 105 (65-150; 20%) 96 (81-132; 15.1%) 108 (66-121; 29%) .53
Dose 4 Cl (mL/min/m2); median (range, CV) 94 (56-141; 21%) 81 (65-128; 18.8%) 92 (58-107; 28.9%) .06
Dose 1 Cmax (ng/mL); median (range, CV) 4,536 (3,498-8,025; 19%) 5,130 (3,849-7,500; 15.7%) 6,246 (5,395-7,494; 16.5%) .005
Dose 4 Cmax (ng/mL); median (range, CV) 4,138 (864-6,492; 37%) 5,439 (3,813-8,883; 24%) 7,326 (2,601-7,888; 487%) <.001
Dose 1 Vd (L/m2); median (range, CV) 24 (14-32; 17%) 23 (11-31; 17.7%) 21 (21-26; 12.4%) .75
Dose 4 Vd (L/m2); median (range, CV) 24 (21-30; 26%) 23 (15-33; 18.3%) 23 (21-27; 12.7%) .91
Dose 1 T1/2 (min); median (range, CV) 162 (128-281; 22%) 168 (81-234; 16.4%) 152 (143-223; 25.4%) .98
Dose 4 T1/2 (min); median (range, CV) 190 (126-245; 16%) 189 (151-237; 12.1%) 174 (159-282; 32.7%) .89
AUC indicates area under the curve; CV, coefficient of variation; Cmax, maximum concentration; Vd, Volume of distribution.
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AUCs outside the target range, the median difference
was 12% below the target (range, 27% below to 21%
above target). The range of doses required to achieve
the target AUC was two fold. For each AUC level,
there was no significant difference between the actual
mean daily AUC obtained and the target AUC
(Table 2).
Pharmacokinetic parameters obtained in this pop-
ulation are similar to those that have been previously
reported in patients receiving IV busulfan on a similar
schedule [26]. As expected, AUC and maximum con-
centrations increased proportionately with increasing
dose administered to achieve target levels. Clearance,
however, was significantly different between dose 1
and dose 4 for all levels (mean dose 1, Cl 103.9 mL/
min/m2 vs mean dose 4, Cl 90.2 mL/min/m2; P \
.001) as was T1/2 (mean dose 1 T1/2 169.9 minutes vs
mean dose 4 T1/2 191.5; P\ .0001). There was no sig-
nificant difference in mean volume of distribution be-
tween dose 1 and dose 4.
Regimen Toxicity
Toxicities graded through day 100 by level are
shown in Table 3. VOD/SOS was the busulfan dose-
limiting toxicity despite ursodiol prophylaxis. None
of 40 patients (0%) on level 1, two of 29 patients
(7%) on level 2, and three of three patients (100%)
on level 3 developed VOD/SOS. Four of the five cases
of VOD/SOSwere biopsy proven. Themedian time to
onset of VOD/SOS in all cases was day 43 (range, 31-
65 days) posttransplantation, and this complication
was significantly associated with actual mean daily
AUCs (P 5 .007). VOD/SOS developed in two of 13
patients (15%) who received sirolimus for eitherGVHD prophylaxis or treatment within 70 days of
transplantation and in three of 59 patients (5%) of
those who did not receive sirolimus (odds ratio, 3.51;
95% confidence interval, 0.25-32.7; P 5 .22). VOD/
SOS developed in zero of six level 1 patients, zero of
five level 2 patients, and two of two level 3 patients
who received sirolimus.
Other significant differences in toxicity between
levels were found in the frequency and severity of hy-
perbilirubinemia, dermatitis, and pulmonary toxicity.
The difference in hyperbilirubinemia was attributable
to VOD/SOS. Although dermatitis was not included
in the original definition of dose-limiting toxicities, it
became a noticeable effect after the study began, so
we started to collect grading information after study
initiation during level 1 accrual. Dermatitis was typi-
cally noted as hyperpigmentation of skin fold areas.
This was most commonly mild and self-limiting, but
at levels 2 and 3, the dermatitis was more generalized,
and patients complained of tenderness in the affected
areas. Patients developing grade 3 and 4 toxicity, expe-
rienced bullae formation and desquamation. Severe
dermatitis was associated with higher mean daily
busulfan AUC levels (P\ .001). With respect to pul-
monary events, one patient on level 1 had a grade 3 in-
terstitial pneumonitis thought to be possibly related to
busulfan, one patient on level 2 had grade 5 pulmonary
edema associated with a grade 5 myocardial infarction,
and one patient on level 3 developed grade 3 dyspnea/
hypoxia related to VOD/SOS-induced ascites. Differ-
ences in cardiac and renal toxicity were of marginal sig-
nificance. There were no seizures associated with
busulfan administration using lorazepam prophylaxis.
Because of the morbidity requiring prolonged hos-
pitalizations and the two deaths in the first three
Table 3. Regimen-Related Toxicitya
AUC Level
P Value
1
6,000
(n 5 40)
2
7,500
(n 5 29)
3
9,000
(n 5 3)
Oral mucositis .74
Grade 0 0 0 0
Grade 1 4 (10%) 1 (3%) 0
Grade 2 15 (37.5%) 15 (53%) 2 (67%)
Grade 3 18 (45%) 11 (38%) 1 (33%)
Grade 4 3 (7.5%) 1 (3%) 0
NE 0 1 (3%) 0
Diarrhea .44
Grade 0 12 (30%) 5 (17%) 0
Grade 1 14 (35%) 8 (28%) 1 (33%)
Grade 2 7 (17.5%) 6 (21%) 2 (67%)
Grade 3 5 (12.5%) 8 (28%) 0
Grade 4 0 1 (3%) 0
NE 2 (5%) 1 (3%) 0
Dysphagiab .23
Grade 0 2 (10%) 2 (7%) 0
Grade 1 2 (10%) 2 (7%) 0
Grade 2 10 (50%) 13 (45%) 1 (33%)
Grade 3 6 (30%) 11 (38%) 2 (67%)
Grade 4 0 0 0
NE 0 1 (3%) 0
Dermatitisc <.01
Grade 0 11 (55%) 6 (21%) 0
Grade 1 4 (20%) 6 (21%) 0
Grade 2 5 (25%) 14 (48%) 1 (33%)
Grade 3 0 3 (10%) 1 (33%)
Grade 4 0 0 1 (33%)
Elevation in transaminases .06
Grade 0 14 (35%) 11 (39%) 0
Grade 1 18 (45%) 9 (30%) 0
Grade 2 3 (7.5%) 6 (21%) 1 (33%)
Grade 3 3 (7.5%) 3 (10%) 2 (67%)
Grade 4 2 (5%) 0 0
Elevation in bilirubin <.01
Grade 0 36 (90%) 18 (62%) 0
Grade 1 3 (7.5%) 4 (14%) 1 (33%)
Grade 2 1 (2.5%) 3 (10%) 0
Grade 3 0 4 (14%) 1 (33%)
Grade 4 0 0 1 (33%)
VOD <.01
None 40 (100%) 27 (93%) 0
Mild 0 0 0
Moderate 0 1 (3.5%) 1 (33%)
Severe 0 1 (3.5%) 2 (67%)
Pulmonary 0.01
Grade 0 25 (62.5%) 22 (77%) 0
Grade 1 0 2 (7%) 0
Grade 2 7 (17.5%) 3 (10%) 2 (67%)
Grade 3 1 (2.5%) 0 1 (33%)
Grade 4 0 0 0
Grade 5 0 1 (3%) 0
NE 7 (17.5%) 1 (3%) 0
Cardiac 0.05
Grade 0 36 (90%) 26 (90%) 1 (33%)
Grade 1 2 (5%) 2 (7%) 1 (33%)
Grade 2 2 (5%) 0 1 (33%)
Grade 3 0 0 0
Grade 4 0 0 0
Grade 5 0 1 (3%) 0
NE 0 0 0
Renal 0.05
Grade 0 26 (65%) 21 (73%) 0
Grade 1 10 (25%) 7 (24%) 2 (67%)
Grade 2 3 (7.5%) 0 1 (33%)
Grade 3 0 1 (3%) 0
(Continued )
Table 3. (Continued )
AUC Level
P Value
1
6,000
(n 5 40)
2
7,500
(n 5 29)
3
9,000
(n 5 3)
Grade 4 0 0 0
NE 1 (2.5%) 0 0
AUC indicates area under the curve; NE, not evaluable; VOD,
veno-occlusive disease.
aNot all patients were evaluable for all toxicities; does not include
complications of infection of graft-versus-host disease (GVHD).
bDysphagia was not recorded on the first 20 level 1 patients;
proportions of level 1 patients based on second 20 patients.
cDermatitis was not recorded on the first 20 level 1 patients;
proportions of level 1 patients based on second 20 patients.
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dose level was halted. Level 2 was declared the maxi-
mally tolerated AUC by protocol definition, and nine
additional patients were enrolled at that level. The pro-
tocol specified 30 patients to be treated at the MTD,
however, accrual was halted after the 29th patient after
observing two cases of VOD/SOS at that level.
Engraftment
All patients had primary engraftment of neutro-
phils; the time to absolute neutrophil count $0.5 
109/L was significantly different between levels (me-
dian [range], level 1: 16 [11-20] days; level 2, 14
[11-22] days; level 3, 12 [11-15] days; P 5 .02).
Platelet recovery was similar: level 1, 16.5 (0-1001)
days; level 2, 16 (0-24) days; and level 3, 17 (15-1001)
days (P 5 .12). There were four patients who never
had a platelet count less than 20  109/L, two on
level 1 and two on level 2. Two patients, one on level
1 and one on level 3, both with myelofibrosis,
remained transfusion-dependent past day 100. Neither
unsorted donor chimerism in the bone marrow, nor
CD3 and CD33 donor chimerisms in peripheral blood
were different between the levels at any of the time
points measured. There were no primary graft failures
at any level.
GVHD
Because the aGVHD prophylactic regimens dif-
fered significantly between the levels, we evaluated
the incidenceofGVHDonly in thosepatients receiving
tacrolimus and MTX. The cumulative incidences of
grade 2 to 4 aGVHD were 87.1% on level 1, 72.7%
on level 2, and 100% on level 3 (P 5 .05). There was
no significant difference in grade 3 to 4 aGVHD (P 5
.76) or chronic GVHD between the levels (P5 .13).
Nonrelapse Mortality, Relapse, and Survival
Themajority of deathswas a result of relapse, infec-
tion, and GVHD and was similar between AUC levels.
Figure 1. Transplantation-related outcomes by predefined area under the curve (AUC) target level. (A), Cumulative incidence of nonrelapse mortality
(P 5 .07). (B), Cumulative incidence of relapse (P 5 .54). (C), Relapse-free survival (P 5 .42). (D), Overall survival (P 5 .25).
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and relapse and Kaplan-Meier plots of overall and
relapse-free survival by level for all patients are shown
in Figure 1. There was no significant difference in
any of these outcome measures between the levels.
When nonrelapse mortality, relapse, and survival
were evaluated by actual mean daily AUC achieved
(\6,000, 6,000-6,999, 7,000-7,999, $8,000 uM-min),
no significant differences were seen between the AUC
groups. We also evaluated these outcomes in patients
receiving tacrolimus andMTX forGVHDprophylaxis
and found that there were significant differences in
nonrelapse mortality, relapse-free, and overall survival
accounted for by the 66% nonrelapse mortality seen
in the level 3 patients. When levels 1 and 2 were com-
pared, no significant differences were observed.DISCUSSION
In large part, the accepted dose of busulfan used in
the HCT setting is based on studies that were doneeither using oral drug, in combination with cyclo-
phosphamide, without pharmacokinetic targeting, or
were retrospective in nature [1-14]. These studies
provided a consensus recommendation of a maximally
tolerated daily exposure of less than 6,000 mM-min 
4 days. We prospectively evaluated the maximally
tolerated systemic exposure of IV busulfan in
combination with fludarabine. Pharmacokinetic dose
targeting allowed more precise delivery of a specific
busulfan AUC. Our findings show that busulfan can
be safely escalated to an AUC of 7,500 mM-min
without an appreciable difference in nonrelapse
mortality. Within the constraints of the small sample
size of an AUC-finding study, relapse and survival
were not improved at theMTD. Caution should be ex-
ercised in the interpretationof thesefindings, as the trial
was not powered to find significant differences in these
outcomes. Our sample size did not allow for subgroup
analysis to evaluate the effect of AUC level in homoge-
neous populations based on diagnosis or disease risk, so
it is possible that a higher AUC could be beneficial in
certain patients.
1106 Biol Blood Marrow Transplant 18:1099-1107, 2012J. B. Perkins et al.In a similar study, O’Donnell et al [27] also
prospectively evaluated the maximally tolerated bu-
sulfan AUC in combination with fludarabine and alem-
tuzumab. Posttransplantation immunosuppression
consisted of tacrolimus alone. They used a test dose
strategy initially but abandoned this practice when
they observed a higher clearance with the test dose,
which inhibited accurate targeting of the conditioning
regimen. Subsequently, they used dose 1 pharmacoki-
netic parameters to target doses 3 and 4, similar to our
study design. Eight patients were treated at level
0 (4,800 mM-min), 13 at level 1 (5,800 mM-min), and
eight at level 2 (6,800 mM-min). As in our study, early
treatment morbidity was minimal, and engraftment
was prompt; nonrelapse mortality overall occurred in
four of 29 patients. VOD/SOS was the dose limiting
toxicity at level 2 (6,800 mM-min), and their maximally
tolerated AUCwas 5,800 mM-min. Eight patients in to-
tal developed VOD/SOS, five of whomwere treated on
level 2. As with our experience, VOD/SOS occurred
later than the 21 days stipulated by theMcDonald crite-
ria [19], with a median time of onset of 52 days (33-77
days) posttransplantation. However, the McDonald
criteria was based on VOD/SOS developing after
cyclophosphamide-based regimens andmay not be rel-
evant for othermyeloablative regimens [28]. InO’Don-
nell’s report, the maximumAUCs differed significantly
between those who did and those who did not develop
VOD/SOS. The incidence of VOD/SOS was higher
in the O’Donnell study compared to our series: eight
of 36 patients (22%) vs five of 72 patients (7%), respec-
tively. This difference may have been due to the higher
incidence of advanced disease in their population, prior
use of gemtuzumab ozogamicin, or inconsistent admin-
istrationof ursodiol.The lower incidenceofVOD/SOS
cases observed in our study overall may also be a result
of excluding patients at risk, such as those with underly-
ing liver disease such as chronic viral hepatitis and
cirrhosis, prior gemtuzumab, and hepatic radiation
exposure.
Wood et al [29] have also reported the results of
their attempt to dose escalate busulfan in combination
with fludarabine. Following pharmacokinetic model-
ing with a 0.8 mg/kg test dose, patients received
a 90-hour continuous infusion of busulfan targeted
to AUCs of 4,800 (nine patients), 5,760 (six patients),
6,912 (eight patients), 7,603 (three patients), or 8,363
(two patients). As with O’Donnell’s study, patients re-
ceived tacrolimus and alemtuzumab for prevention of
GVHD. Patients with high-risk hematologic malig-
nancies with HLA-matched related or unrelated do-
nors were included. All patients engrafted. There
were nine treatment-related deaths: seven from infec-
tion, one from late VOD/SOS (day 201; patient
treated on AUC 5,760 level), and one from leukoence-
phalopathy. Similar to our study, the maximally toler-
ated AUC was 7,603 mm/min per day for 4 days. TheDLT was grade 4 mucositis (two of two patients at
the AUC 8,363 level) with an actual mean AUC of
9,600 mmol*min/hour per day for 4 days. Of interest
is that VOD/SOS was not dose-limiting, perhaps be-
cause of the continuous infusion administration that
avoids high peak busulfan exposures.
We successfully dosed patients to their target AUC
in 88% of cases, despite significant differences in bu-
sulfan clearance observed between dose 1 and dose 4.
Those patients who were not targeted successfully
had substantial changes in either clearance or volumes
of distribution between AUC measurements, making
targeting more difficult. The reasons for these changes
are unclear but could have included the use of concom-
itant medications during the dosing interval that have
unknown effects on busulfan metabolism, changes in
fluid status secondary to diuresis or hydration, random
sampling error, or laboratory error. Yeh et al [30] also
reported a declining clearance over a daily dosing
interval. The reduction in clearance was more pro-
nounced in patients receiving fludarabine compared
to those receiving cyclophosphamide. The authors
recommended targeting busulfan to the lower end of
the desired target level when busulfan is given in com-
bination with fludarabine to compensate for the re-
duced clearance over the dosing interval.
In our prospective escalation of busulfan AUC, we
saw excessive morbidity and mortality at a targeted
level of AUC of 9,000 mM-min and determined that
the maximum tolerated AUC was 7,500 mM-min.
Examination of the three patients treated at the
9,000 mM-min AUC revealed that all met study eligi-
bility criteria and were not at increased risk of VOD/
SOS. The combination of fludarabine and busulfan
targeted to 7,500 mM-min should be tested for relapse
prevention in a more homogeneous patient population
at high risk for relapse. For standard-risk patients,
a busulfan target of 6,000 mM-min can be used safely
in combination with fludarabine.ACKNOWLEDGMENTS
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